2-Aminoindane

hypertension, coronary artery disease, arrhythmias, structural cardiac abnormalities, tachyarrhythmia

2-AI acts as a norepinephrine releasing agent via NET substrate activity. The resulting sympathomimetic activation produces dose-dependent increases in heart rate and blood pressure. Pre-existing cardiovascular conditions magnify the risk of acute cardiac events. Computational toxicity models predict an 80% probability of cardiovascular toxicity as the primary organ system affected.

epilepsy, seizure-prone conditions

Norepinephrine-releasing stimulants lower seizure threshold as a class effect. Individuals with epilepsy or other seizure-prone conditions face elevated risk of breakthrough seizures. No 2-AI-specific seizure data exist, but the mechanism is well-characterized for NET-releasing agents.

generalized anxiety disorder, panic disorder

2-AI's primary mechanism — norepinephrine release — directly activates the arousal and stress-response systems. Individuals with pre-existing anxiety disorders may experience exacerbation of symptoms, panic attacks, or agitation, particularly at higher doses.

severe liver disease, hepatic impairment

2-AI undergoes no CYP-mediated oxidative metabolism in human liver microsomes. Its sole clearance pathway is NAT2 acetylation in the liver (Manier 2020). Severe hepatic impairment would further reduce an already polymorphism-dependent clearance mechanism, potentially leading to dangerously elevated plasma concentrations of unchanged 2-AI.

NAT2 slow acetylator genotype

2-AI is metabolized exclusively by polymorphic NAT2. Slow acetylators (40–60% of Caucasian populations) have reduced capacity to clear the parent compound, resulting in higher and more prolonged plasma concentrations. This pharmacogenomic consideration is unique to 2-AI among recreational stimulants and warrants conservative dose selection in individuals who know or suspect slow acetylator status.

hyperthyroidism, thyrotoxicosis

Hyperthyroidism increases baseline sympathetic tone. Additional norepinephrine release from 2-AI may compound cardiovascular and CNS effects, increasing risk of tachycardia, hypertension, and agitation.

pregnancy, lactation

No reproductive toxicity data exist for 2-AI. Sympathomimetic stimulants as a class are associated with uterine vasoconstriction and fetal growth restriction. The absence of any safety data combined with the known sympathomimetic mechanism mandates avoidance during pregnancy and lactation.

MAOI therapy, moclobemide, phenelzine, tranylcypromine, selegiline

Monoamine oxidase inhibitors block the enzymatic degradation of norepinephrine in the synaptic cleft. When combined with a NET releasing agent like 2-AI, the resulting accumulation of norepinephrine can trigger hypertensive crisis, serotonin syndrome (at high doses), and potentially fatal cardiovascular collapse. This is a well-established class-level contraindication for all monoamine releasing agents.

SSRIs, SNRIs, serotonergic medications

Despite 2-AI's weak SERT activity, the Pinterova 2017 review states that aminoindanes 'may pose a significant risk of serotonin syndrome at high doses or when combined with other drugs.' Concurrent use of SSRIs or SNRIs could impair serotonin clearance sufficiently to produce serotonin syndrome when combined with even weak serotonergic release from 2-AI at high doses.